# A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

> **NCT03114657** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 806 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Crenezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03114657
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-29
- **Primary completion:** 2019-06-11
- **Final completion:** 2019-06-11
- **Target enrollment:** 806 (ACTUAL)
- **Why stopped:** This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03114657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03114657, "A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03114657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*